Zantac Mass Tort Marketing Campaigns for Lawyers

The lawsuits accuse the companies of negligence, claiming they ignored evidence showing that ranitidine could degrade into NDMA when exposed to heat or over time. Plaintiffs believe the companies prioritized profits over safety by not testing the drug thoroughly or issuing recalls sooner.

These cases continue to move forward in both federal and state courts, with more than 70,000 active lawsuits currently pending. Some cases have already resulted in settlements, while others have gone to trial after judges rejected drugmakers’ appeals.

If your law firm is looking to launch a Zantac mass tort marketing campaign, you need to act quickly to secure qualified leads. With thousands of individuals affected by Zantac’s NDMA contamination, the potential client base is significant, but so is the competition. A well-executed campaign can help your firm connect with people who need legal representation following Zantac-related cancer diagnoses. Partnering with an experienced marketing team like TSEG will allow your firm to attract the right clients, generate consistent leads, and stay ahead in this competitive space.

Zantac, also known by its generic name ranitidine, was introduced in the 1980s as a treatment for heartburn, acid reflux, and ulcers. Developed by GlaxoSmithKline, Zantac quickly became one of the most popular medications worldwide, with millions of people using it every day. By the late 1980s, it was the best-selling drug in the world, with more than $1 billion in sales. For decades, doctors prescribed Zantac in both prescription and over-the-counter forms, believing it to be safe for long-term use.

However, concerns about Zantac began to surface in 2019. Scientists discovered that ranitidine, the active ingredient in Zantac, could break down into a chemical called NDMA, a known carcinogen. Studies showed that when Zantac was exposed to heat or stored for long periods, it produced dangerous levels of NDMA, far exceeding the FDA’s safe daily limits.

In response, the FDA issued a public warning in 2020 and requested that manufacturers pull Zantac from the market. This led to a wave of lawsuits by individuals who had used Zantac regularly and were later diagnosed with cancer. Many of these lawsuits claim that Zantac caused cancers such as bladder, stomach, liver, pancreatic, and esophageal cancer.

Plaintiffs argue that drug companies failed to warn consumers about the risks and continued to sell Zantac despite knowing it could degrade into a harmful substance. Today, Zantac litigation continues to grow as more people come forward with claims related to their cancer diagnoses. 

Zantac litigation has seen several significant developments in recent months. Thousands of lawsuits focusing on Zantac’s contamination with NDMA remain active, with plaintiffs claiming the heartburn drug caused their cancer. Despite early victories for some defendants, the litigation is far from over.

In June 2024, Delaware judge Vivian Medinilla allowed over 70,000 Zantac lawsuits to move forward. This ruling came after the judge decided that expert witnesses could testify about the drug’s potential to cause cancer. This decision was a setback for pharmaceutical companies like GlaxoSmithKline, Pfizer, Sanofi, and Boehringer Ingelheim, which had previously won dismissals in many federal cases. These companies continue to face thousands of lawsuits in state courts across the country.

At the same time, recent trials have produced mixed results. In some state courts, defendants have won cases, such as a recent trial in Illinois where the jury ruled in favor of drugmakers, rejecting claims that Zantac causes colon cancer. Many cases are settling before going to trial, as companies aim to avoid the risk of large jury verdicts. For example, GlaxoSmithKline and Sanofi have settled several lawsuits confidentially, including recent cases in California and Illinois.

TSEG’s Zantac mass tort campaigns are designed to help your law firm reach clients who need legal representation for cancer diagnoses related to Zantac use. TSEG understands the high level of competition in this area and offers customized marketing strategies to give your firm a competitive edge.

With a deep understanding of mass tort marketing, TSEG builds campaigns that target people most likely to be suffering from health issues after using Zantac. Our team uses data-driven strategies, including search engine optimization (SEO), pay-per-click (PPC) advertising, and content marketing, to ensure your law firm’s marketing efforts reach the right audience. These tools help your firm stand out in search results, driving potential clients to your website.

We focus on creating clear, compelling messaging that connects with Zantac users who might not know that their cancer diagnosis could be linked to the medication. TSEG ensures your marketing materials explain the connection between NDMA contamination and cancer in a way that resonates with potential clients. By doing so, we help your firm build trust with those seeking legal help.

TSEG also monitors your campaign performance in real time, optimizing as necessary to ensure you get the best return on your marketing investment. Our goal is to help your firm generate consistent, qualified leads while building strong client relationships. With TSEG, you can confidently grow your client base in the Zantac mass tort space and stay ahead of the competition.

Take your Zantac mass tort campaigns to the next level with TSEG. We’ve got the tools, strategies, and experience to help your firm cut through the noise and speak directly to claimants who need your representation. Reach out online or call us today at (512) 394-7234, and let’s start building a winning campaign that delivers real results.